Cargando…
Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation
BACKGROUND: Watch and wait (WW) protocols have gained increasing popularity for patients diagnosed with locally advanced rectal cancer and presumed complete clinical response after neoadjuvant chemoradiation. While studies have demonstrated comparable survival and recurrence rates between WW and rad...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810473/ https://www.ncbi.nlm.nih.gov/pubmed/34529175 http://dx.doi.org/10.1245/s10434-021-10576-z |
_version_ | 1784644260736270336 |
---|---|
author | Cui, Christina Liu Luo, William Yu Cosman, Bard Clifford Eisenstein, Samuel Simpson, Daniel Ramamoorthy, Sonia Murphy, James Lopez, Nicole |
author_facet | Cui, Christina Liu Luo, William Yu Cosman, Bard Clifford Eisenstein, Samuel Simpson, Daniel Ramamoorthy, Sonia Murphy, James Lopez, Nicole |
author_sort | Cui, Christina Liu |
collection | PubMed |
description | BACKGROUND: Watch and wait (WW) protocols have gained increasing popularity for patients diagnosed with locally advanced rectal cancer and presumed complete clinical response after neoadjuvant chemoradiation. While studies have demonstrated comparable survival and recurrence rates between WW and radical surgery, the decision to undergo surgery has significant effects on patient quality of life. We sought to conduct a cost-effectiveness analysis comparing WW with abdominoperineal resection (APR) and low anterior resection (LAR) among patients with stage II/III rectal cancer. METHODS: In this comparative-effectiveness study, we built Markov microsimulation models to simulate disease progression, death, costs, and quality-adjusted life-years (QALYs) for WW or APR/LAR. We assessed cost effectiveness using the incremental cost-effectiveness ratio (ICER), with ICERs under $100,000/QALY considered cost effective. Probabilities of disease progression, death, and health utilities were extracted from published, peer-reviewed literature. We assessed costs from the payer perspective. RESULTS: WW dominated both LAR and APR at a willingness to pay (WTP) threshold of $100,000. Our model was most sensitive to rates of distant recurrence and regrowth after WW. Probabilistic sensitivity analysis demonstrated that WW was the dominant strategy over both APR and LAR over 100% of iterations across a range of WTP thresholds from $0–250,000. CONCLUSIONS: Our study suggests WW could reduce overall costs and increase effectiveness compared with either LAR or APR. Additional clinical research is needed to confirm the clinical efficacy and cost effectiveness of WW compared with surgery in rectal cancer. |
format | Online Article Text |
id | pubmed-8810473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88104732022-02-11 Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation Cui, Christina Liu Luo, William Yu Cosman, Bard Clifford Eisenstein, Samuel Simpson, Daniel Ramamoorthy, Sonia Murphy, James Lopez, Nicole Ann Surg Oncol Colorectal Cancer BACKGROUND: Watch and wait (WW) protocols have gained increasing popularity for patients diagnosed with locally advanced rectal cancer and presumed complete clinical response after neoadjuvant chemoradiation. While studies have demonstrated comparable survival and recurrence rates between WW and radical surgery, the decision to undergo surgery has significant effects on patient quality of life. We sought to conduct a cost-effectiveness analysis comparing WW with abdominoperineal resection (APR) and low anterior resection (LAR) among patients with stage II/III rectal cancer. METHODS: In this comparative-effectiveness study, we built Markov microsimulation models to simulate disease progression, death, costs, and quality-adjusted life-years (QALYs) for WW or APR/LAR. We assessed cost effectiveness using the incremental cost-effectiveness ratio (ICER), with ICERs under $100,000/QALY considered cost effective. Probabilities of disease progression, death, and health utilities were extracted from published, peer-reviewed literature. We assessed costs from the payer perspective. RESULTS: WW dominated both LAR and APR at a willingness to pay (WTP) threshold of $100,000. Our model was most sensitive to rates of distant recurrence and regrowth after WW. Probabilistic sensitivity analysis demonstrated that WW was the dominant strategy over both APR and LAR over 100% of iterations across a range of WTP thresholds from $0–250,000. CONCLUSIONS: Our study suggests WW could reduce overall costs and increase effectiveness compared with either LAR or APR. Additional clinical research is needed to confirm the clinical efficacy and cost effectiveness of WW compared with surgery in rectal cancer. Springer International Publishing 2021-09-16 2022 /pmc/articles/PMC8810473/ /pubmed/34529175 http://dx.doi.org/10.1245/s10434-021-10576-z Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Colorectal Cancer Cui, Christina Liu Luo, William Yu Cosman, Bard Clifford Eisenstein, Samuel Simpson, Daniel Ramamoorthy, Sonia Murphy, James Lopez, Nicole Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation |
title | Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation |
title_full | Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation |
title_fullStr | Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation |
title_full_unstemmed | Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation |
title_short | Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation |
title_sort | cost effectiveness of watch and wait versus resection in rectal cancer patients with complete clinical response to neoadjuvant chemoradiation |
topic | Colorectal Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810473/ https://www.ncbi.nlm.nih.gov/pubmed/34529175 http://dx.doi.org/10.1245/s10434-021-10576-z |
work_keys_str_mv | AT cuichristinaliu costeffectivenessofwatchandwaitversusresectioninrectalcancerpatientswithcompleteclinicalresponsetoneoadjuvantchemoradiation AT luowilliamyu costeffectivenessofwatchandwaitversusresectioninrectalcancerpatientswithcompleteclinicalresponsetoneoadjuvantchemoradiation AT cosmanbardclifford costeffectivenessofwatchandwaitversusresectioninrectalcancerpatientswithcompleteclinicalresponsetoneoadjuvantchemoradiation AT eisensteinsamuel costeffectivenessofwatchandwaitversusresectioninrectalcancerpatientswithcompleteclinicalresponsetoneoadjuvantchemoradiation AT simpsondaniel costeffectivenessofwatchandwaitversusresectioninrectalcancerpatientswithcompleteclinicalresponsetoneoadjuvantchemoradiation AT ramamoorthysonia costeffectivenessofwatchandwaitversusresectioninrectalcancerpatientswithcompleteclinicalresponsetoneoadjuvantchemoradiation AT murphyjames costeffectivenessofwatchandwaitversusresectioninrectalcancerpatientswithcompleteclinicalresponsetoneoadjuvantchemoradiation AT lopeznicole costeffectivenessofwatchandwaitversusresectioninrectalcancerpatientswithcompleteclinicalresponsetoneoadjuvantchemoradiation |